Risk of tuberculosis after recent exposure: A 10-year follow-up study of contacts in Amsterdam

American Journal of Respiratory and Critical Care Medicine

Volumn 190, Issue 9, 2014, Pages 1044-1052

  Sloot, Rosa ^a,b   Van Der Loeff, Maarten F Schim ^b,c   Kouw, Peter M ^c   Borgdorff, Martien W ^a,b,c  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c DEPARTMENT OF INFECTIOUS DISEASES   (Netherlands)

Author keywords

Follow up; Preventive therapy; Tuberculosis contact investigation; Tuberculosis incidence

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; BCG VACCINATION; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; FOLLOW UP; GENOTYPE; HUMAN; INCIDENCE; INFANT; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; NEWBORN; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; PUBLIC HEALTH SERVICE; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCREENING; TUBERCULIN TEST; MIDDLE AGED; NETHERLANDS; PRESCHOOL CHILD; TIME; TRANSMISSION; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INFANT; MALE; MIDDLE AGED; NETHERLANDS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; TIME FACTORS; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 84922391496     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201406-1159OC     Document Type: Article

References (29)

1. American Thoracic Society. Targeted tuberculin and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000;161: S221-S247.
2. Styblo K. The relationship between the risk of tuberculous infection and the risk of developing infectious tuberculosis. Bull Int Union Tuberc Lung Dis 1985;60:117-119.
3. Macintyre CR, Plant AJ, Hendrie D. The cost-effectiveness of evidence-based guidelines and practice for screening and prevention of tuberculosis. Health Econ 2000;9:411-421.
4. Jasmer RM, Snyder DC, Saukkonen JJ, Hopewell PC, Bernardo J, King MD, Kawamura LM, Daley CL; Short-Course Rifampin and Pyrazinamide for Tuberculosis Infection Study Investigators. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a cost-effectiveness analysis based on a multicenter clinical trial. Clin Infect Dis 2004;38:363-369.
5. Salpeter SR, Sanders GD, Salpeter EE, Owens DK. Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: a risk-benefit and cost-effectiveness analysis. Ann Intern Med 1997;127:1051-1061.
6. Pina JM, Clotet L, Ferrer A, Sala MR, Garrido P, Salleras L, Domínguez A. Cost-effectiveness of rifampin for 4 months and isoniazid for 9 months in the treatment of tuberculosis infection. Eur J Clin Microbiol Infect Dis 2013;32:647-655.
7. Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis: a general review. Bibl Tuberc 1970;26:28-106.
8. Comstock GW, Baum C, Snider DE Jr. Isoniazid prophylaxis among Alaskan Eskimos: a final report of the bethel isoniazid studies. Am Rev Respir Dis 1979;119:827-830.
9. Comstock GW, Livesay VT, Woolpert SF. The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol 1974;99:131-138.
10. Comstock GW. Frost revisited: the modern epidemiology of tuberculosis. Am J Epidemiol 1975;101:363-382.
11. Sutherland I, Svandová E, Radhakrishna S. The development of clinical tuberculosis following infection with tubercle bacilli. 1. A theoretical model for the development of clinical tuberculosis following infection, linking from data on the risk of tuberculous infection and the incidence of clinical tuberculosis in the Netherlands. Tubercle 1982;63:255-268.
12. Vynnycky E, Fine PE. Lifetime risks, incubation period, and serial interval of tuberculosis. Am J Epidemiol 2000;152:247-263.
13. Zelner JL, Murray MB, Becerra MC, Galea J, Lecca L, Calderon R, Yataco R, Contreras C, Zhang Z, Grenfell BT, et al. Bacillus Calmette-Gué rin and isoniazid preventive therapy protect contacts of patients with tuberculosis. Am J Respir Crit Care Med 2014;189:853-859.
14. Ayieko J, Abuogi L, Simchowitz B, Bukusi EA, Smith AH, Reingold A. Efficacy of isoniazid prophylactic therapy in prevention of tuberculosis in children: a meta-analysis. BMC Infect Dis 2014;14:91.
15. Vynnycky E, Borgdorff MW, Leung CC, Tam CM, Fine PE. Limited impact of tuberculosis control in Hong Kong: attributable to high risks of reactivation disease. Epidemiol Infect 2008;136:943-952.
16. Fox GJ, Barry SE, Britton WJ, Marks GB. Contact investigation for tuberculosis: a systematic review and meta-analysis. Eur Respir J 2013;41:140-156.
17. Supply P, Allix C, Lesjean S, Cardoso-Oelemann M, Rüsch-Gerdes S, Willery E, Savine E, de Haas P, van Deutekom H, Roring S, et al . Proposal for standardization of optimized mycobacterial interspersed repetitive unit-variable-number tandem repeat typing of Mycobacterium tuberculosis. J Clin Microbiol 2006;44:4498-4510.
18. van Embden JD, Cave MD, Crawford JT, Dale JW, Eisenach KD, Gicquel B, Hermans P, Martin C, McAdam R, Shinnick TM, et al. Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology. J Clin Microbiol 1993;31:406-409.
19. KNCV Tuberculosis Foundation. Landelijke Coördinatie Infectieziektebestrijding. Richtlijn Tuberculosecontactonderzoek. The Hague: KNCV; 2007.
20. KNCV Tuberculosis Foundation. IGRA-werkgroep Commissie voor Praktische Tuberculosebestrijding. Richtlijn Interferon Gamma Release Assays bij de diagnostiek van tuberculose. The Hague: KNCV; 2007.
21. European Centre for Disease Prevention and Control. Use of interferongamma release assays in support of TB diagnosis. Stockholm: ECDC; 2011.
22. Schaaf JM, Hof MH, Mol BW, Abu-Hanna A, Ravelli AC. Recurrence risk of preterm birth in subsequent twin pregnancy after preterm singleton delivery. BJOG 2012;119:1624-1629.
23. Tromp M, Reitsma JB, Ravelli AC, Méray N, Bonsel GJ. Record linkage: making the most out of errors in linking variables. AMIA Annu Symp Proc 2006;779 -783.
24. Therneau TM. A package for survival analysis in R. R package version 2.37-7 [accessed 2014 Mar 5]. Available from: http://CRAN.Rproject.org/package=survival
25. Beyers N, Gie RP, Schaaf HS, Van Zyl S, Talent JM, Nel ED, Donald PR. A prospective evaluation of children under the age of 5 years living in the same household as adults with recently diagnosed pulmonary tuberculosis. Int J Tuberc Lung Dis 1997;1:38-43.
26. Morán-Mendoza O, Marion SA, Elwood K, Patrick D, FitzGerald JM. Risk factors for developing tuberculosis: a 12-year follow-up of contacts of tuberculosis cases. Int J Tuberc Lung Dis 2010;14:1112-1119.
27. Farhat M, Greenaway C, Pai M, Menzies D. False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria? Int J Tuberc Lung Dis 2006;10:1192-1204.
28. Berkel GM, Cobelens FG, de Vries G, Draayer-Jansen IW, Borgdorff MW. Tuberculin skin test: estimation of positive and negative predictive values from routine data. Int J Tuberc Lung Dis 2005;9:310-316.
29. Kik SV, Franken WP, Mensen M, Cobelens FG, Kamphorst M, Arend SM, Erkens C, Gebhard A, Borgdorff MW, Verver S. Predictive value for progression to tuberculosis by IGRA and TST in immigrant contacts. Eur Respir J 2010;35:1346-1353.